We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+8.72%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
-$17.9M
(-24%)
Cap. Flow
-$4.42M
Cap. Flow
% of AUM
-7.61%
Top 10 Holdings %
Top 10 Hldgs %
43.93%
Holding
340
New
63
Increased
59
Reduced
56
Closed
151
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$2.31M |
| 2 |
Amgen
AMGN
|
+$1.97M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$1.79M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$1.56M |
| 5 |
Clorox
CLX
|
+$1.3M |
Top Sells
| 1 |
Abbott
ABT
|
+$5.02M |
| 2 |
Akebia Therapeutics
AKBA
|
+$3.63M |
| 3 |
FL
Foot Locker
FL
|
+$2.12M |
| 4 |
General Mills
GIS
|
+$2.03M |
| 5 |
lululemon athletica
LULU
|
+$1.38M |
Sector Composition
| 1 | Healthcare | 37.51% |
| 2 | Consumer Staples | 17.11% |
| 3 | Consumer Discretionary | 2.69% |
| 4 | Communication Services | 1.36% |
| 5 | Materials | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TWX
51
DELISTED
Time Warner Inc
TWX
| $246K | 0.42% |
2,450
-9,935
| -80% | -$984K |
|
|
52
PUT
General Mills
GIS
$20.7B
| $239K | 0.41% |
63,000
-61,600
| -49% | -$3.52M |
|
53
Alnylam Pharmaceuticals
ALNY
$37.8B
| $234K | 0.4% |
2,938
-1,888
| -39% | -$121K |
|
|
AERI
54
DELISTED
Aerie Pharmaceuticals
AERI
| $230K | 0.4% |
+4,375
| New | +$204K |
|
|
SIOX
55
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $227K | 0.39% |
+1,226
| New | +$215K |
|
|
AVXS
56
CALL
DELISTED
AveXis, Inc. Common Stock
AVXS
| $220K | 0.38% |
21,000
+3,800
| +22% | +$285K |
|
57
Larimar Therapeutics
LRMR
$381M
| $214K | 0.37% |
5,089
-5,072
| -50% | -$259K |
|
|
58
PUT
Clorox
CLX
$11.9B
| $201K | 0.35% |
35,600
-3,600
| -9% | -$486K |
|
59
PUT
Regeneron Pharmaceuticals
REGN
$71.2B
| $194K | 0.33% |
13,000
+9,500
| +271% | +$4.16M |
|
60
Agilent Technologies
A
$38.4B
| $192K | 0.33% |
+3,236
| New | +$184K |
|
|
NBRV
61
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $170K | 0.29% |
60
-19
| -24% | -$49K |
|
|
SVVC
62
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
| $168K | 0.29% |
20,000
-2,238
| -10% | -$18.7K |
|
|
63
PUT
iShares Biotechnology ETF
IBB
$9.23B
| $165K | 0.28% |
69,000
+3,000
| +5% | +$295K |
|
64
Harley-Davidson
HOG
$2.82B
| $160K | 0.28% |
+2,954
| New | +$164K |
|
65
Textron
TXT
$15.8B
| $159K | 0.27% |
+3,371
| New | +$159K |
|
|
CLVS
66
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $156K | 0.27% |
64,600
+48,200
| +294% | +$2.95M |
|
67
PUT
Mondelez International
MDLZ
$78.8B
| $150K | 0.26% |
65,000
-5,100
| -7% | -$230K |
|
68
PUT
Incyte
INCY
$23.3B
| $142K | 0.24% |
14,000
+5,000
| +56% | +$636K |
|
69
CALL
Insmed
INSM
$23.3B
| $141K | 0.24% |
70,000
+8,500
| +14% | +$145K |
|
70
PUT
Illumina
ILMN
$28.8B
| $138K | 0.24% |
+7,299
| New | +$1.26M |
|
71
CALL
Colgate-Palmolive
CL
$75.3B
| $126K | 0.22% |
64,800
+5,800
| +10% | +$431K |
|
72
CALL
Coca-Cola Europacific Partners
CCEP
$46.9B
| $125K | 0.22% |
33,000
+25,000
| +313% | +$990K |
|
|
73
PUT
Insmed
INSM
$23.3B
| $121K | 0.21% |
107,600
+22,600
| +27% | +$386K |
|
74
PUT
DaVita
DVA
$15B
| $113K | 0.19% |
33,500
+22,500
| +205% | +$1.49M |
|
|
OTIC
75
PUT
DELISTED
Otonomy, Inc.
OTIC
| $113K | 0.19% |
56,300
+41,300
| +275% | +$576K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2017 Portfolio in Review
As of Q2 2017, FT Options held 340 positions worth $58.1M, down 24% from $76M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
FT Options withdrew a net $4.42M in Q2 2017, closing 151 positions and reducing 56 holdings. Its most notable exit was Foot Locker, an estimated $2.12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, FT Options opened a new position in Amgen worth $2.08M.
- FT Options's largest Q2 2017 buy was Amgen: 12,082 shares worth $2.08M.
- FT Options added most to Clovis Oncology, Inc. in Q2 2017, an estimated $2.31M increase.
- FT Options's biggest Q2 2017 reduction was Abbott, cutting an estimated $5.02M.
- FT Options fully exited Foot Locker in Q2 2017, selling an estimated $2.12M.
- FT Options's ten largest holdings make up 44% of its $58.1M portfolio in Q2 2017.
- FT Options opened 63 new positions and closed 151 in Q2 2017.
- FT Options's portfolio value fell 24% quarter-over-quarter to $58.1M.
Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.